ArticleNucleic acids research2026
Enhancing prediction accuracy for enzyme activity engineering through sequence co-evolution and epistatic relationship modeling.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Conventional enzyme engineering strategies, such as directed evolution with structure-based analysis, are limited by laborious workflows and by the need to screen extensive enzyme libraries. Computational models based on multiple sequence alignment, such as SCANEER, have streamlined these engineering strategies, enabling the successful prediction of single-site mutations that enhance enzyme activity. However, when combining predicted mutations to improve enzyme performance or expand mutational space, such approaches often fail due to epistatic interactions among amino acid residues, which can lead to complex, non-additive effects. Here, we present epiSCANEER, an extended computational framework that incorporates co-evolutionary dependencies reflecting residue-level epistatic effects to identify mutation combinations with a higher likelihood of enhancing enzyme activity. By evaluating amino acid pairs at co-evolved positions across homologous sequences, epiSCANEER prioritizes mutation combinations with high evolutionary compatibility, significantly narrowing the combinatorial search space to variants more likely to exhibit activity-enhancing effects. Experimental validation demonstrated a 76% success rate for epiSCANEER prediction, compared to 30% and 38% for single-site predictions and combinatorial approaches of single-site mutants, respectively. This novel method obviates the need to construct single-mutation libraries, significantly reducing labor and costs while improving success rates. epiSCANEER has been developed as a web-server that enables researchers to access tools for rational enzyme optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.